OSAKA, Japan--(BUSINESS WIRE)--Feb. 14, 2006--Santen Pharmaceutical Co., Ltd. (President: Takakazu Morita) announced preliminary results of the overseas clinical trials of two drug candidates for lowering intraocular pressure in glaucoma and ocular hypertension: an angiotensin II receptor antagonist, DE-092 (INN: Olmesartan), and a prostaglandin derivative, DE-085 (INN: Tafluprost).
